CURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD.

OXNARD, Calif., May 24, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, announced today that it has received their first purchase order from their recently announced agreement with diverse international pharmaceutical company Meroven Ltd. for the development of oral thin film (OTF) delivery for several molecules, including Vitamin D3.

Meroven has placed their first order of 150,000 units of the Vitamin D3 OTF to be distributed to the Middle East. Vitamin D is a fat-soluble vitamin that is naturally present in very few foods, added to others, and available as a dietary supplement. It is also produced endogenously when ultraviolet rays from sunlight strike the skin and trigger Vitamin D synthesis. Vitamin D promotes calcium absorption and is needed for bone growth. Vitamin D also prevents rickets in children and osteomalacia in adults. Together with calcium, Vitamin D also helps protect older adults from osteoporosis.

Additionally, a leading direct to consumer distribution company has placed an order for 867,000 melatonin blend sleep drug OTFs, to sell to distributors. 

“We are thrilled that two of our development and licensing agreements are now at the stage where they will be distributing the product to people all over the world and we look forward to working with these institutions and many others on future drug developments,” said Rob Davidson, CEO of CURE. “CURE’s mission is to develop relationships with other companies to develop and commercialize new applications of proven therapeutics, all with the goal to provide greater benefit to the end user and the provider and all through our proprietary drug delivery technologies.”

About CURE Pharmaceutical
Headquartered in Oxnard, California, CURE Pharmaceutical (OTC:CURR) is a fully integrated specialty pharmaceutical/bioscience company that leverages disruptive proprietary drug delivery technologies for a broad range of molecules serving the biopharmaceutical, veterinarian, medical foods and pharmaceutical cannabis markets. CURE develops its patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today, from its industry leading full service cGMP manufacturing facility. The Company’s mission is to deliver proven drugs in a fast and efficient manner and to improve quality of life.

For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com. 

Forward-looking statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. 

Contact:

Andrew Hard 
CMW Media
[email protected]
917.660.5418